MedTrace Logo

The Effects of Cilnidipine on Metabolic Syndrome Improvement

NCT00325936 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 186

Last updated 2008-08-27

No results posted yet for this study

Summary

Abnormalities of glucose, insulin and lipoprotein metabolism are common in patients with hypertension, and these metabolic abnormalities are reported to be related to insulin resistance. Therefore, whenever treating such patients, antihypertensive agents that may have the added effect of improving insulin resistance should be selected. CinalongTM (Cilnidipine) is expected to improve metabolic syndrome as well as insulin resistance by its dual effects on L and N-type calcium (Ca) channels. In this study, the researchers investigate the effects of CinalongTM on insulin resistance and other metabolic related factors.

Conditions

Interventions

DRUG

Cilnidipine

10\~20mg, qd, po for 3 months or 12 months.

Sponsors & Collaborators

  • Boryung Pharmaceutical Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Jeong Bae Park, Ph.D. · Cheil General Hospital and Women's Healthcare Center

  • Sang-hyun Lim, Ph.D. · Catholic University Holy Family Hospital

  • Ho-joong Youn, Ph.D. · Catholic University St Mary's Hospital (Yeouido)

  • Yeong-geun An, Ph.D. · Chonnam National University Hospital

  • Dong-su Kim, Ph.D. · Inje University

  • Seong-yun Lee, Ph.D. · Inje University Ilsan Paik Hospital

  • Heon-sik Park, Ph.D. · Kyungpook National University Hospital

  • Ji-dong Seong, Ph.D. · Samsung Medical Center

  • In-ho Chae, Ph.D. · Seoul National University Bundang Hospital

  • Se-joong Im, Ph.D. · Youngdong Severance Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-07-31
Primary Completion
2007-06-30
Completion
2007-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00325936 on ClinicalTrials.gov